CGTX - Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTAD | Benzinga
PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ:CGTX), (the "Company" or "Cognition") announced that Willem de Haan, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers' Alzheimer Center, is presenting complete EEG findings from the Phase 2 SEQUEL study at the Clinical Trials on Alzheimer's Disease (CTAD) conference. SEQUEL was conducted at the Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg, M.D., Ph.D., acting as principal investigator. The poster describing changes in brain wave patterns in adults with mild-to-moderate Alzheimer's disease following 28-days of treatment with CT1812 or placebo will be on display through the conclusion of CTAD.
In the SEQUEL study, CT1812-treated participants exhibited a statistically significant change in relative theta in the central region of the brain and consistent trends of improvement across all prespecified EEG parameters. In particular, improvements were seen in global relative theta power (p=0.123) and in global relative alpha power (p=0.149), as well as in connectivity, as assessed by alpha AECc (p=0.034), which may indicate improved communication between different parts of the brain.
Synaptic dysfunction is observed early in the Alzheimer's disease process and is correlated with subsequent cognitive decline. There is substantial evidence to believe that quantitative electroencephalography (qEEG) can be used to measure this decline of electrical activity in the brain. In Alzheimer's disease, cognitive decline is associated with increasing prominence of slower EEG frequencies (4-8 Hz) termed "theta" and a declining prominence of "alpha" frequencies (8-12 Hz), which are the dominant brainwaves in cognitively normal individuals. The measures of connectivity between regions of the brain are believed to be as critical as regional measures of brain activity when assessing disease.
"CT1812 treatment showed improvement of EEG parameters that are consistent in magnitude and effect size with previously reported trials," explained Dr. de Haan. "Notably, these positive changes occurred after only a short treatment interval. To see this measurable result in a matter of weeks in individuals with mild-to-moderate disease is exciting and provides optimism that CT1812 is altering underlying Alzheimer's disease processes."
The poster being presented by Dr. de Hann will be available on the Cognition Therapeutics website along with additional content relevant to the company's CTAD presentations at https://cogrx.com/ctad2023.
About CT1812
CT1812 is an experimental orally delivered small molecule sigma-2 (?-2) receptor modulator designed to penetrate the blood-retinal barrier and bind selectively and saturably to the ...